The AHA July 20 submitted comments on proposed Centers for Medicare & Medicaid Services regulations that would support state flexibility in Medicaid drug value-based purchasing arrangements and other changes to the Medicaid drug rebate program for fiscal year 2021.

“The AHA supports innovations in drug purchasing arrangements, so long as these arrangements preserve or enhance patient access to critical medications and result in lower drug costs,” AHA wrote. “As CMS continues to pursue an increase in VBP opportunity, we urge the agency to consider the appropriate balance that must be struck to make these arrangements work effectively for the Medicaid program as well as throughout the health care delivery system.”

AHA also urged the agency to extend the comment period beyond the current 30-day period to allow stakeholders’ thoughtful and careful consideration for assessing the implications of applying VBP arrangements for Medicaid drug coverage and purchasing.

Related News Articles

Headline
The Congressional Budget Office today released its estimate of the budgetary effects of the One Big Beautiful Bill Act, as enacted. CBO projects the law will…
Headline
The Centers for Medicare & Medicaid Services July 17 issued two letters to states regarding policies on continuous eligibility and workforce initiatives.…
Headline
Sen. Josh Hawley, R-Mo., July 15 introduced legislation that would repeal some of the Medicaid funding reductions included in the recently enacted One Big…
Headline
The House July 3 voted 218-214 to pass the final version of the One Big Beautiful Bill Act (H.R. 1), which enacts many of President Trump’s legislative…
Headline
The Senate narrowly passed the One Big Beautiful Bill Act (H.R. 1) on July 1 by a 50-50 tally, with Vice President J.D. Vance casting the tie-breaking vote.…
Headline
The AHA June 29 sent a letter to senators urging them to amend the budget reconciliation bill before its final passage in the Senate. The Senate version of the…